Cambridge-based biotech company Spirea has raised $3 million to advance a new generation of antibody-drug conjugate (ADC) therapeutics.
The round was co-led by Jonathan Milner and Cambridge Enterprise, with backing from R42 Group, ACF Investors, o2h Ventures, Syndicate Room and Cambridge Angels.
The funding will enable the company to start its pipeline of superior and differentiated ADCs in the treatment of solid tumors where there is a high unmet need.
Spirea has developed a new approach to building ADCs that allows more drug payloads to be specifically directed to the target tumor cell.
This results in an increase in therapeutic effect whilst substantially reducing debilitating side effects.
According to the company, its technology can unlock accessible and well-tolerated medicines for the treatment of a wide range of cancers by delivering the right amount of the right drug to the right cells.
Read more on Tech Gist Africa:
